Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Abstract, Academy, adagrasib, AEs, aforementioned, al, anemia, Apr, arm, atezolizumab, Australia, begun, bevacizumab, Biden, biliary, Bio, Biogen, Biology, bioresearch, biweekly, BNP, BTC, Cadillac, CBR, CDMO, cholangiocarcinoma, classification, combat, compliant, concomitant, conduit, constantly, constitutionality, correctly, cultural, dataset, dealing, deliverance, DGPR, dismissed, dissemination, diversified, DOR, driven, durable, earnout, EC, elevated, Elpiscience, endothelial, excessive, excise, explore, female, FGFR, fourth, freely, front, Fuji, gastrointestinal, GMP, gouging, Goyal, Handok, harbor, harboring, hypertension, implicit, Importantly, Indian, infigratinib, inflation, instated, instructed, ipilimumab, irinotecan, IRS, issuable, Japan, Kalled, Korea, Korean, lab, laid, largest, leasehold, Leerink, linear, locked, main, male, microvasculature, Miranda, Modernization, Molecular, month, moratorium, MTD, NaN, Nasdaq, neutropenia, nivolumab, notified, onward, Ophthalmology, ovarian, paclitaxel, pancreatic, Parliament, path, pemigatinib, plenary, plot, PR, preapproval, pretreated, prominent, prostate, PRs, pulmonary, reconciled, reconsider, regorafenib, regression, relaxing, remitted, remote, renamed, rescinded, resume, RSU, RUL, Russia, SAE, salvage, scan, SCLC, SD, session, shelf, Simon, Sixteen, sotorasib, Susan, SVB, taxation, TEAE, tiered, Toledano, tracing, tract, trigr, TTP, unconfirmed, uninterruptedly, unnecessary, unresectable, unused, upfront, urge, vascular, vascularization, virtue, Vol, waterfall, wholly, York
Filing tables
Filing exhibits
CMPX similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Compass Therapeutics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date: March 18, 2022 |
| By: | /s/ Thomas Schuetz |
|
|
| Thomas Schuetz |
|
|
| Principal Executive Officer |